Gennex Laboratories Ltd
BSE: GENNEX · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Gennex Laboratories Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Gennex Laboratories Limited is an India-based pharmaceutical company specialising in the manufacturing and distribution of active pharmaceutical ingredients (APIs) and bulk drugs. Its core product portfolio includes expectorants, muscle relaxants, and analgesic agents, with a focus on products like Guaifenesin and Methocarbamol.
Business Model
The company operates a cost-effective manufacturing model, leveraging its Telangana-based facility to supply the global generic pharmaceutical supply chain. It generates revenue through both domestic sales and international exports across Asia, Europe, and the Americas.
Management Commentary
Management is focused on scaling manufacturing capacity and enhancing research capabilities to solidify the company's standing in the global bulk drug industry.
Growth Outlook
Growth is driven by the expansion of manufacturing capacity and strategic partnerships within the global pharmaceutical supply chain. The company aims to strengthen its market position by adhering to international quality standards.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining international quality standards at its manufacturing facilities, which are subject to stringent global regulatory inspections.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can significantly impact the company's production costs and profit margins.
- Geopolitical and Export Risks. As an exporter to multiple continents, the company is exposed to currency fluctuations, trade barriers, and changes in international pharmaceutical import regulations.
- Competitive Pricing. The generic bulk drug industry is highly competitive, putting constant pressure on pricing and requiring continuous cost-optimisation to maintain market share.
Start your research today
Unlock AI insights, financials, peers and live data on Gennex Laboratories Ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹173 Cr
TTM · consolidated
NET PROFIT
₹21 Cr
TTM · consolidated
EPS
₹0.81
TTM · consolidated
RETURN ON EQUITY
10.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
12.1%
TTM · consolidated
P/E
12.1x
Q4 FY26 · consolidated
EV/EBITDA
8.9x
Q4 FY26 · consolidated
EBITDA MARGIN
17.6%
TTM · consolidated
NET PROFIT MARGIN
7.3%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Gennex Laboratories LtdGENNEX | ₹235 Cr | 12.10 | 8.90 | 25.3% | 17.6% | 10.7% | 12.1% | -18.2% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Gennex Laboratories Ltd
BSE: GENNEX · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Gennex Laboratories Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Gennex Laboratories Limited is an India-based pharmaceutical company specialising in the manufacturing and distribution of active pharmaceutical ingredients (APIs) and bulk drugs. Its core product portfolio includes expectorants, muscle relaxants, and analgesic agents, with a focus on products like Guaifenesin and Methocarbamol.
Business Model
The company operates a cost-effective manufacturing model, leveraging its Telangana-based facility to supply the global generic pharmaceutical supply chain. It generates revenue through both domestic sales and international exports across Asia, Europe, and the Americas.
Management Commentary
Management is focused on scaling manufacturing capacity and enhancing research capabilities to solidify the company's standing in the global bulk drug industry.
Growth Outlook
Growth is driven by the expansion of manufacturing capacity and strategic partnerships within the global pharmaceutical supply chain. The company aims to strengthen its market position by adhering to international quality standards.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining international quality standards at its manufacturing facilities, which are subject to stringent global regulatory inspections.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can significantly impact the company's production costs and profit margins.
- Geopolitical and Export Risks. As an exporter to multiple continents, the company is exposed to currency fluctuations, trade barriers, and changes in international pharmaceutical import regulations.
- Competitive Pricing. The generic bulk drug industry is highly competitive, putting constant pressure on pricing and requiring continuous cost-optimisation to maintain market share.
Start your research today
Unlock AI insights, financials, peers and live data on Gennex Laboratories Ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹173 Cr
TTM · consolidated
NET PROFIT
₹21 Cr
TTM · consolidated
EPS
₹0.81
TTM · consolidated
RETURN ON EQUITY
10.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
12.1%
TTM · consolidated
P/E
12.1x
Q4 FY26 · consolidated
EV/EBITDA
8.9x
Q4 FY26 · consolidated
EBITDA MARGIN
17.6%
TTM · consolidated
NET PROFIT MARGIN
7.3%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26